Study wrapper · #948
Multi-target incretin-based therapeutics: The rise of dual and triple agonists for metabolic disorders.
Alavi SE, Boshrouyeh R, Raza A, et al. European journal of medicinal chemistry. 2026.
DOI: 10.1016/j.ejmech.2026.118587PubMed: 41547240
Editor's note
A narrative overview of the mechanisms and clinical progress of multi-target incretin agonists. It covers tirzepatide and retatrutide as leading examples but breaks no new ground, noting open questions on safety, access, and long-term use. Suitable as background reading rather than primary evidence.
Plain-language abstract
A review summarizing how dual and triple incretin agonists such as tirzepatide and retatrutide are being studied for type 2 diabetes, obesity, and fatty liver disease.
Related coverage
Weak / none
Cost-effectiveness of tirzepatide versus semaglutide for patients with obesity or overweight in the US: evidence from the SURMOUNT-5 head-to-head phase-3 trial.
Journal of medical economicsn=——2026
Weak / none
Tirzepatide attenuates lipopolysaccharide-induced acute lung injury via AMPK/NF-κB signaling pathway.
Tissue & celln=——2026
Mixed
Real-world treatment satisfaction and experience with once-weekly tirzepatide: Insights from prescribing physicians and people with obesity or overweight.
Obesity pillarsn=——2026